TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03321097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: condensed RT group
Description: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distributed RT group
Description: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.
Study: NCT03861143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 (440 mg)
Description: Oral, once daily tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 (880 mg)
Description: Oral, once daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily tablet
Study: NCT04763070

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin Oral Product
Description: The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
Study: NCT03188445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Administered iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate with ascorbic acid
Description: Oral administration
Study: NCT02541773

Intervention type: DEVICE
Intervention: Cardiac Resynchronisation Therapy
Description: Routine implantation of CRT - part of standard of care
Study: NCT03042936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insulin Superheroes Club Curriculum
Description: This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
Study: NCT03063580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Pharmaceutical form: capsules~Route of administration: oral
Study: NCT01119456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3
Study: NCT04285567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
Study: NCT02875353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler Endoscopic Probe
Description: A colon length catheter (probe).
Study: NCT01119456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-RON8
Description: 20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8
Study: NCT02361216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study: NCT04583397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radio frequency electromagnetic fields
Description: Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radio frequency electromagnetic fields
Description: Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
Study: NCT01380457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Capsules, 10 mg, single dose, fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol
Description: Capsules, 10 mg, single-dose, fasting conditions
Study: NCT02549755

Intervention type: DRUG
Group type: OTHER
Intervention: 11C-Acetate
Description: The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient
Study: NCT04124588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexpowder (Hemostatic powder)
Description: Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Technique
Description: Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Technique
Description: Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
Study: NCT04856709

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal Pectopexy
Description: Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal Sacral Hysteropexy
Description: Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
Study: NCT02200185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV titrated morphine
Description: Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~* SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose nebulised morphine
Description: 10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose nebulised morphine
Description: 20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
Study: NCT02945631

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PTV56
Description: total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PTV50.4
Description: total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
Study: NCT00751868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
Study: NCT00494143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CESR Prosthetic Foot
Description: a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: typical prosthetic foot
Description: patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standardized prosthetic foot
Description: a standard foot that has had weights applied to match the mass of the CESR foot
Study: NCT02905175

Intervention type: PROCEDURE
Intervention: blood sample

Intervention type: PROCEDURE
Intervention: blood sample

Intervention type: PROCEDURE
Intervention: synovial tissue
Description: synoviocytes from synovial tissue

Intervention type: PROCEDURE
Intervention: synovial tissue
Description: synoviocytes from synovial tissue
Study: NCT03771742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transverse scan, in-plane, posterior-anterior TMQLB
Description: The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paramedian sagittal scan, in-plane, caudal-cranial TMQLB
Description: The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
Study: NCT02447848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil sublingual 30 mcg tablet
Study: NCT01034995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR125543
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR125543
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR125543
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Pharmaceutical form: encapsulated tablets~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02587338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum tDCS
Description: Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anodal, right cathodal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
Study: NCT03281980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Description: i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Government Intervention (UCT+HE)
Description: fgbfgjhgykghilk
Study: NCT03914976

Intervention type: PROCEDURE
Intervention: patient having to undergo a high risk programmed digestive surgery
Description: The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
Study: NCT03781648

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NBI withdrawal method
Description: The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NBI withdrawal method
Description: The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
Study: NCT03847142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASTHMAXcel mobile application
Description: ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient primary care
Description: Usual care delivered through the outpatient primary care setting
Study: NCT03233854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19/CD22 CAR T cells IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: Given IV
Study: NCT02098564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobility exercises hand therapy
Description: Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobility exercises hand therapy
Description: Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobility exercises hand therapy
Description: Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity-based hand therapy
Description: intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity-based hand therapy
Description: intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity-based hand therapy
Description: intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
Study: NCT03379662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS Laser
Description: The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
Study: NCT02579980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE and DWI MRI
Description: Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care procedure for sarcoma patients
Study: NCT03657043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: Intravenous (IV) infusion
Study: NCT02356562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet
Study: NCT01411748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reflor
Description: 5 million unit/day, orally, beginning on the second day of life, until discharge from hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mikostatin
Description: 50000 unit/3 times a day, both for orally and by orogastric route
Study: NCT01700933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Dosage Exercise Therapy
Description: Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dosage Exercise Therapy
Description: Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)
Study: NCT01610765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novel Antiviral Drug
Description: 4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
Study: NCT01281462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil and NXL104 (q8h)
Description: 600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil and NXL104 (q12h)
Description: 600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg doripenem IV q8h;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
Study: NCT02794675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesium 131
Description: The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.